Pre-op chemoradiotherapy ups survival in esophageal cancer

May 31, 2012
Pre-Op chemoradiotherapy ups survival in esophageal cancer
For patients with esophageal or esophagogastric-junction cancer, treatment with neoadjuvant chemoradiotherapy followed by surgical resection is associated with improved survival compared with surgery alone, according to a study published in the May 31 issue of the New England Journal of Medicine.

(HealthDay) -- For patients with esophageal or esophagogastric-junction cancer, treatment with neoadjuvant chemoradiotherapy followed by surgical resection is associated with improved survival compared with surgery alone, according to a study published in the May 31 issue of the New England Journal of Medicine.

Peter van Hagen, M.C.C.M., from the Erasmus University Medical Center in Rotterdam, Netherlands, and colleagues investigated the role of neoadjuvant chemoradiotherapy in the treatment of 366 patients with resectable esophageal or esophagogastric-junction cancer (275 with , 84 with squamous-cell carcinoma, and seven with large-cell undifferentiated carcinoma). Participants, enrolled from March 2004 through December 2008, were randomly allocated to receive surgery alone (188 patients) or to receive carboplatin and paclitaxel for five weeks with concurrent radiotherapy, followed by surgery (178 patients).

The researchers found that 92 percent of patients in the chemoradiotherapy-surgery group achieved complete resection with no tumor within 1 mm of the resection margins, compared with 69 percent in the surgery-alone group. Twenty-nine percent of patients who underwent resection after chemoradiotherapy achieved a pathological complete response. In the two treatment groups, were similar, with 4 percent in-hospital mortality in both groups. The median overall survival was 49.4 and 24.0 months in the chemoradiotherapy-surgery and surgery-alone groups, respectively. In the chemoradiotherapy-surgery group, overall survival was significantly improved (hazard ratio, 0.657; P = 0.003).

"Preoperative chemoradiotherapy (five courses of and , with 41.4 Gy of concurrent radiotherapy) is safe and leads to a significant increase in overall survival among patients with adenocarcinoma or squamous-cell carcinoma of the esophagus or esophagogastric junction," the authors write.

More information: Full Text (subscription or payment may be required)

Related Stories

Early response is an indicator for rectal cancer survival

April 10, 2012

(HealthDay) -- In patients with locally advanced rectal cancer undergoing radical resection, response to neoadjuvant chemoradiotherapy is an early marker that correlates with rates of recurrence-free survival, distant metastases, ...

Recommended for you

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Modified DNA building blocks are cancer's Achilles heel

July 22, 2015

In studying how cells recycle the building blocks of DNA, Ludwig Cancer Research scientists have discovered a potential therapeutic strategy for cancer. They found that normal cells have highly selective mechanisms to ensure ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.